XBiotech Names Founder's 24-Year-Old Son Co-CEO With 2M Option Grant
XBIT is trading near its 52-week low of $1.8 (1.1% above the low).
Summary
XBiotech appointed Dr. Sushma Shivaswamy and 24-year-old Jan-Paul Simard, son of the founder, as Co-CEOs effective October 23, 2026. Simard receives a $150,000 salary and 2,000,000 stock options vesting over three years.
Key Events · Executive and Board Changes · XBIT
-
Co-CEOs Appointed
Effective October 23, 2026, the Board named Dr. Sushma Shivaswamy and Jan-Paul Simard Co-Chief Executive Officers; Shivaswamy, interim CEO since December 2025, retains the CSO title.
-
Founder's Son Gets Top Role
Jan-Paul Simard, age 24, is the son of founder and former CEO John Simard; he joined XBiotech in 2012 as an R&D assistant and moved to clinical development in 2020.
-
2M Option Grant
Under his employment agreement dated October 26, 2026, Simard receives a $150,000 base salary and 2,000,000 options struck at the closing price on the effective date, vesting 1/6 every six months over three years.
-
Perks and Retention Terms
The agreement reimburses reasonable business use of John Simard's private aircraft and lets Simard retain a pro-rata share of options if employment ends before full vesting.
Analysis · XBIT · Life Sciences
The governance optics are the story here: XBiotech has split the CEO role between its long-tenured chief scientist and Jan-Paul Simard, the 24-year-old son of founder John Simard, who retired in December 2025. A first-time executive with no prior C-suite or board experience takes half the CEO job at a $150,000 salary, and his employment agreement includes a 2,000,000-share option grant plus reimbursement for business use of his father's private aircraft. Against a $1.82 stock, that grant is a large equity stake for a company this size, and it lands just as the company reported positive Phase II data for vilamakitug on October 19. Investors will weigh whether the scientific leadership of Dr. Shivaswamy offsets the thin operational track record of the co-CEO.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 30.7% of the 1698 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XBIT was trading at $1.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $55.5M. The 52-week trading range was $1.80 to $3.44. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.